Evolus reports Q4 EPS (21c), consensus (7c)

Reports Q4 revenue $61M, consensus $60.06M. “2023 was a defining year for Evolus. We achieved record market share as the fastest growing toxin in the U.S. for the third consecutive year, expanded our portfolio globally with the addition of an innovative late-stage line of facial fillers, and delivered continued improvement in operating income performance,” said David Moatazedi, President and Chief Executive Officer of Evolus. “We expect to be profitable1 for the fourth quarter of 2024 and the full year 2025.”